Skip to main content
. 2012 Nov 30;7(11):e50925. doi: 10.1371/journal.pone.0050925

Table 2. Toxic effects recorded from randomized controlled trials (Grade 3–4 Adverse Events).

Studies Intervention Neutro-penia Skin toxicity Diarrhea Thrombocytopenia Sensory neuropathy Fatigue
COIN [13] FOLFOX/XELOX 13% <1% 14% 3% 18% 18%
FOLFOX/XELOX+Cetuximab 12% 20% 24% 3% 14% 26%
Nordic VII [14] FLOX 47% 1% 10% 3% 22% 10%
FLOX+Cetuximab 46% 22% 17% 4% 16% 16%
OPUS [11], [12] FOLFOX4 34% 0.6% 7% 2% 7% 3%
FOLFOX4+ Cetuximab 30% 11% 8% 4% 4% 4%
PRIME [15], [16] FOLFOX4 41% 2% 9% 16% 3%
FOLFOX4+Panitumumab 42% 36% 18% 16% 9%